A Day Late and a Billion Dollars Short: TMC's Angiomax Patent Nightmare
Executive Summary
The Medicines Co. stands to lose $1 billion in revenues from a clerical mistake in a patent extension request; the company, arguing patients will lose, continues to ask Congress to help fix it. But in a Democratic congress, the fight is distinctly uphill.
You may also be interested in...
The Medicines Company CEO Clive Meanwell, An Interview With "The Pink Sheet" DAILY, (Part 1 Of 3)
While fighting for a patent extension for its sales leader, the specialty pharma has adjusted its business model to include acquisitions and early-stage drug development.
Start-Up Quarterly Statistics, Q3 2008
Start-Up analyzes fundraising and alliances among emerging companies in the biopharmaceutical, medical device and in vitro diagnostics segments from July through September 2008. Data comes from FDC-Windhover's Strategic Transactions Database.
Carotid Stenting: Trials and Tribulations
Today, carotid artery stenting is an accepted less-invasive alternative to surgical endarterectomy for carefully selected patients, particularly those at significant surgical risk, and market projections are very positive. But, the field still has a long way to go before this procedure is considered routine.